Neuren Pharmaceuticals Ltd
ASX:NEU

Watchlist Manager
Neuren Pharmaceuticals Ltd Logo
Neuren Pharmaceuticals Ltd
ASX:NEU
Watchlist
Price: 12.2 AUD -0.41% Market Closed
Market Cap: 1.6B AUD
Have any thoughts about
Neuren Pharmaceuticals Ltd?
Write Note

Intrinsic Value

The intrinsic value of one NEU stock under the Base Case scenario is 7.07 AUD. Compared to the current market price of 12.2 AUD, Neuren Pharmaceuticals Ltd is Overvalued by 42%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NEU Intrinsic Value
7.07 AUD
Overvaluation 42%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Neuren Pharmaceuticals Ltd

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
NEU
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for NEU cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about NEU?
Bearish
Neutral
Bullish

Fundamental Analysis

12.2 AUD
-0.41%
-0.41%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Neuren Pharmaceuticals Ltd
AU
Pharmaceuticals
Market Cap
1.6B AUD
IPO
Feb 3, 2005
Employees
-
Australia
Market Cap
1.6B AUD
Industry
Pharmaceuticals
IPO
Feb 3, 2005
Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Neuren Pharmaceuticals Ltd

Provide an overview of the primary business activities
of Neuren Pharmaceuticals Ltd.

What unique competitive advantages
does Neuren Pharmaceuticals Ltd hold over its rivals?

What risks and challenges
does Neuren Pharmaceuticals Ltd face in the near future?

Has there been any significant insider trading activity
in Neuren Pharmaceuticals Ltd recently?

Summarize the latest earnings call
of Neuren Pharmaceuticals Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Neuren Pharmaceuticals Ltd.

Provide P/S
for Neuren Pharmaceuticals Ltd.

Provide P/E
for Neuren Pharmaceuticals Ltd.

Provide P/OCF
for Neuren Pharmaceuticals Ltd.

Provide P/FCFE
for Neuren Pharmaceuticals Ltd.

Provide P/B
for Neuren Pharmaceuticals Ltd.

Provide EV/S
for Neuren Pharmaceuticals Ltd.

Provide EV/GP
for Neuren Pharmaceuticals Ltd.

Provide EV/EBITDA
for Neuren Pharmaceuticals Ltd.

Provide EV/EBIT
for Neuren Pharmaceuticals Ltd.

Provide EV/OCF
for Neuren Pharmaceuticals Ltd.

Provide EV/FCFF
for Neuren Pharmaceuticals Ltd.

Provide EV/IC
for Neuren Pharmaceuticals Ltd.

Show me price targets
for Neuren Pharmaceuticals Ltd made by professional analysts.

What are the Revenue projections
for Neuren Pharmaceuticals Ltd?

How accurate were the past Revenue estimates
for Neuren Pharmaceuticals Ltd?

What are the Net Income projections
for Neuren Pharmaceuticals Ltd?

How accurate were the past Net Income estimates
for Neuren Pharmaceuticals Ltd?

What are the EPS projections
for Neuren Pharmaceuticals Ltd?

How accurate were the past EPS estimates
for Neuren Pharmaceuticals Ltd?

What are the EBIT projections
for Neuren Pharmaceuticals Ltd?

How accurate were the past EBIT estimates
for Neuren Pharmaceuticals Ltd?

Compare the revenue forecasts
for Neuren Pharmaceuticals Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Neuren Pharmaceuticals Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Neuren Pharmaceuticals Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Neuren Pharmaceuticals Ltd compared to its peers.

Compare the P/E ratios
of Neuren Pharmaceuticals Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Neuren Pharmaceuticals Ltd with its peers.

Analyze the financial leverage
of Neuren Pharmaceuticals Ltd compared to its main competitors.

Show all profitability ratios
for Neuren Pharmaceuticals Ltd.

Provide ROE
for Neuren Pharmaceuticals Ltd.

Provide ROA
for Neuren Pharmaceuticals Ltd.

Provide ROIC
for Neuren Pharmaceuticals Ltd.

Provide ROCE
for Neuren Pharmaceuticals Ltd.

Provide Gross Margin
for Neuren Pharmaceuticals Ltd.

Provide Operating Margin
for Neuren Pharmaceuticals Ltd.

Provide Net Margin
for Neuren Pharmaceuticals Ltd.

Provide FCF Margin
for Neuren Pharmaceuticals Ltd.

Show all solvency ratios
for Neuren Pharmaceuticals Ltd.

Provide D/E Ratio
for Neuren Pharmaceuticals Ltd.

Provide D/A Ratio
for Neuren Pharmaceuticals Ltd.

Provide Interest Coverage Ratio
for Neuren Pharmaceuticals Ltd.

Provide Altman Z-Score Ratio
for Neuren Pharmaceuticals Ltd.

Provide Quick Ratio
for Neuren Pharmaceuticals Ltd.

Provide Current Ratio
for Neuren Pharmaceuticals Ltd.

Provide Cash Ratio
for Neuren Pharmaceuticals Ltd.

What is the historical Revenue growth
over the last 5 years for Neuren Pharmaceuticals Ltd?

What is the historical Net Income growth
over the last 5 years for Neuren Pharmaceuticals Ltd?

What is the current Free Cash Flow
of Neuren Pharmaceuticals Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Neuren Pharmaceuticals Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Neuren Pharmaceuticals Ltd

Current Assets 228m
Cash & Short-Term Investments 213.2m
Receivables 14.9m
Non-Current Assets 110k
PP&E 35k
Other Non-Current Assets 75k
Current Liabilities 9m
Accounts Payable 4.5m
Other Current Liabilities 4.5m
Non-Current Liabilities 29k
Other Non-Current Liabilities 29k
Efficiency

Earnings Waterfall
Neuren Pharmaceuticals Ltd

Revenue
204.2m AUD
Operating Expenses
-38.2m AUD
Operating Income
166m AUD
Other Expenses
-48.7m AUD
Net Income
117.3m AUD

Free Cash Flow Analysis
Neuren Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

NEU Profitability Score
Profitability Due Diligence

Neuren Pharmaceuticals Ltd's profitability score is 63/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional 3-Years Revenue Growth
Exceptional ROE
Exceptional ROIC
63/100
Profitability
Score

Neuren Pharmaceuticals Ltd's profitability score is 63/100. The higher the profitability score, the more profitable the company is.

NEU Solvency Score
Solvency Due Diligence

Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NEU Price Targets Summary
Neuren Pharmaceuticals Ltd

Wall Street analysts forecast NEU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NEU is 27.99 AUD with a low forecast of 23.13 AUD and a high forecast of 32.49 AUD.

Lowest
Price Target
23.13 AUD
90% Upside
Average
Price Target
27.99 AUD
129% Upside
Highest
Price Target
32.49 AUD
166% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NEU?

Click here to dive deeper.

Dividends

Neuren Pharmaceuticals Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for NEU is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

NEU Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?
What is the Intrinsic Value of one NEU stock?

The intrinsic value of one NEU stock under the Base Case scenario is 7.07 AUD.

Is NEU stock undervalued or overvalued?

Compared to the current market price of 12.2 AUD, Neuren Pharmaceuticals Ltd is Overvalued by 42%.

Back to Top